-
Mashup Score: 0
This study represents the largest analysis so far of the α-synuclein SAA for the biochemical diagnosis of Parkinson’s disease. Our results show that the assay classifies people with Parkinson’s disease with high sensitivity and specificity, provides information about molecular heterogeneity, and detects prodromal individuals before diagnosis. These findings suggest a crucial role for the…
Source: The Lancet NeurologyCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0
This study represents the largest analysis so far of the α-synuclein SAA for the biochemical diagnosis of Parkinson’s disease. Our results show that the assay classifies people with Parkinson’s disease with high sensitivity and specificity, provides information about molecular heterogeneity, and detects prodromal individuals before diagnosis. These findings suggest a crucial role for the…
Source: The Lancet NeurologyCategories: Latest Headlines, NeurologyTweet-
In our May issue, Andrew Siderowf and colleagues used data from the @MichaelJFoxOrg PPMI cohort to assess whether alpha-synuclein seed amplification (aSyn-SAA) could effectively identify heterogeneity among people with and at-risk of Parkinson's disease. https://t.co/f3HkkoS2Sw
-
-
Mashup Score: 0
The ideal biomarker to revolutionise the understanding, diagnosis, and treatment of Parkinson’s disease should fulfill three criteria. First, establish a diagnosis of Parkinson’s disease and differentiate it from related disorders with high sensitivity and specificity. Second, detect Parkinson’s disease in its earliest stages, ideally in the prodromal phase. Third, demonstrate target engagement…
Source: The Lancet NeurologyCategories: Latest Headlines, NeurologyTweet-
In a linked Comment, Daniela Berg and Christine Klein believe that aSyn-SAA is a game-changer in Parkinson's disease research, but say that longitudinal analysis of aSyn-SAA is now needed https://t.co/P3wwpasUIJ
-
-
Mashup Score: 2New therapies for autoimmune myasthenia gravis - 1 year(s) ago
Myasthenia gravis is a rare, chronic autoimmune disease of the neuromuscular junction that is characterised by muscle weakness. Most people with the disease have antibodies against one of the transmembrane proteins at the synapse, such as the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK). Activation of complement by AChR antibodies is thought to be one of the key…
Source: The Lancet NeurologyCategories: Latest Headlines, NeurologyTweet-
In our May issue, two Articles report phase 3 data for new drugs for myasthenia gravis. In a linked Comment, Jan Verschuuren discusses how these two new drugs target this neuromuscular disorder, and how they fit within a growing therapeutic landscape. https://t.co/aS2xo2mple https://t.co/LsEOsrA7TV
-
-
Mashup Score: 1
Rozanolixizumab showed clinically meaningful improvements in patient-reported and investigator-assessed outcomes in patients with generalised myasthenia gravis, for both 7 mg/kg and 10 mg/kg doses. Both doses were generally well tolerated. These findings support the mechanism of action of neonatal Fc receptor inhibition in generalised myasthenia gravis. Rozanolixizumab represents a potential…
Source: The Lancet NeurologyCategories: Latest Headlines, NeurologyTweet-
In the first Article, Vera Bril and colleagues report findings of the MycarinG trial, which assessed the safety and efficacy of the neonatal Fc receptor blocker rozanolixizumab for patients with generalised myasthenia gravis https://t.co/GgCmlfYOPy
-
-
Mashup Score: 1
Zilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings. Zilucoplan is a new potential treatment option for a broad population of patients with AChR-positive generalised myasthenia gravis. The long-term safety and efficacy of zilucoplan is being…
Source: The Lancet NeurologyCategories: Latest Headlines, NeurologyTweet-
In the second Article, James Howard Jr and colleagues report findings of the RAISE trial, looking at the safety and efficacy of the complement C5 inhibitor zilucoplan in patients with generalised myasthenia gravis https://t.co/zxU6W9Sitn
-
-
Mashup Score: 234
This study represents the largest analysis so far of the α-synuclein SAA for the biochemical diagnosis of Parkinson’s disease. Our results show that the assay classifies people with Parkinson’s disease with high sensitivity and specificity, provides information about molecular heterogeneity, and detects prodromal individuals before diagnosis. These findings suggest a crucial role for the…
Source: The Lancet NeurologyCategories: Expert Picks, Latest HeadlinesTweet-
A significant advance for #Parkinsons disease: the biomarker α-synuclein is an accurate classifier, detects very early (prodromal), and a target for Rx as determined in a large cohort with controls https://t.co/NEQUzefu0n @TheLancetNeuro https://t.co/v7IBfpkgSL
-
-
Mashup Score: 22
This study represents the largest analysis so far of the α-synuclein SAA for the biochemical diagnosis of Parkinson’s disease. Our results show that the assay classifies people with Parkinson’s disease with high sensitivity and specificity, provides information about molecular heterogeneity, and detects prodromal individuals before diagnosis. These findings suggest a crucial role for the…
Source: The Lancet NeurologyCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
NEW—Identifying ‘hallmark’ Parkinson’s disease protein build-up could aid early detection and pave way for improved diagnosis and treatment , a new study published in @TheLancetNeuro suggests https://t.co/AgXx2ZCsb2 https://t.co/TmwiVi1aIK
-
-
Mashup Score: 0The artificial dichotomy of body and brain - 1 year(s) ago
Medical phenomena such as alien limbs and agnosia have always captured the imagination and curiosity of researchers, clinicians, and the general public. These conditions are traditionally considered disorders of the brain, and an unfortunate consequence of the misfiring of groups of rebellious neurons. The limbs and the rest of the body are commonly perceived as plain transducers receiving…
Source: The Lancet NeurologyCategories: Latest Headlines, PsychiatryTweet-
"Costandi expertly reviews the literature regarding the complex and multistage process of how the brain perceives the rest of the body and how that perception is incorporated into a sense of the self." New book review in @TheLancetNeuro https://t.co/xZITPm1xPT
-
-
Mashup Score: 0Targeting tau degradation: a viable therapeutic approach? - 1 year(s) ago
The tauopathies are a diverse group of neurodegenerative diseases that are defined by the misfolding of tau—a microtubule binding protein—and its assembly into filamentous intracellular deposits. Primary tauopathies, in which tau inclusions are the principal pathological hallmark, highlight the neurotoxic nature of tau. In Alzheimer’s disease, tau inclusions co-exist with extracellular plaques of…
Source: The Lancet NeurologyCategories: Latest Headlines, NeurologyTweet-
A new Comment, just published online, by @SpillantiniLab discusses whether targeting tau degradation is a viable therapeutic approach. https://t.co/bqYTaBQAD3 https://t.co/Fa4X07etcb
-
New test may be able to predict person’s risk of developing Parkinson’s disease https://t.co/LZbvUFu947